Trial · NCT02523976
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
NCT02523976, Phase 2, Completed, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Trials, record NCT02523976. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02523976
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- NCT number
- NCT02523976
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Acute,Leukemia, Lymphoid
- Interventions
Dasatinib, prednisone, cyclophosphamide, daunorubicin, vincristine, cytarabine, mercaptopurine, methotrexate, dexamethasone, mitoxantrone, etoposide, allogeneic hematopoietic stem cell transplantation, autologous hematopoietic stem cell transplantation
- First posted
- 2015-08-14
- Last updated
- 2026-02-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival (OS) | From date of diagnosis until the date of death from any cause, assessed up to 60 months. | |
| Secondary | Disease-free survival (DFS) | From the date of complete remission(CR) until the date of documented relapse,assessed up to 60 months. | |
| Secondary | The complete remission (CR) rate | Participants will be followed for the duration of the treatment, an expected average of 6 months. | |
| Secondary | The molecular CR rate | Participants will be followed for the duration of the treatment, an expected average of 24 months. | |
| Secondary | The plasma level of dasatinib in the regimen | Up to 3 months. | |
| Secondary | The Cerebrospinal fluid level of dasatinib in the regimen | Up to 6 months. | |
| Secondary | Number of adverse event of combined treatment | Participants will be followed for the duration of the treatment, an expected average of 24 months. | |
| Secondary | Grade of adverse event of combined treatment | Participants will be followed for the duration of the treatment, an expected average of 24 months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02523976
GET https://conductscience.org/api/trials/v1/NCT02523976/registered